Table 1. Open in new tab Demographics...

Race/ethnicity
N		8	37	135	4	2205	11	6	45
Mean age (years)		33.9 ± 15.2	41.9 ± 16.1	43.2 ± 15.3	29.5 ± 6.6	47.2 ± 17.4	42.1 ± 16.1	44.1 ± 14.9	41.4 ± 18.9	.001
Sex	Male	3 (37.5%)	19 (51.4%)	65 (48.2%)	0 (0.0%)	1024 (46.4%)	6 (54.5%)	3 (50.0%)	18 (40.0%)	.62
BMI		28.0 ± 5.7	25.3 ± 5.9	29.8 ± 8.0	25.5 ± 3.7	28.0 ± 6.5	26.3 ± 6.0	27.8 ± 5.7	25.5 ± 5.7	.001
Diagnosis	Crohn’s disease	5 (62.5%)	16 (43.2%)	98 (72.6%)	1 (25.0%)	1371 (62.2%)	5 (45.5%)	3 (50.0%)	19 (42.2%)
Ulcerative Colitis	3 (37.5%)	21 (56.8%)	37 (27.4%)	3 (75.0%)	828 (37.6%)	6 (54.5%)	3 (50.0%)	26 (57.8%)	.043
Other	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mean IBD duration (years)		10.3 ± 9.8	9.4 ± 10.1	12.9 ± 9.9	9.2 ± 6.8	15.1 ± 12.6	16.2 ± 8.4	20.6 ± 16.1	12.2 ± 12.4	.016
IBD treatment	5-ASA	4	15	22	1	578	3	2	19
AZA or monotherapy	0	5	10	0	168	0	0	1
MTX monotherapy	0	0	2	0	24	0	0	0
anti-TNF monotherapy	3	7	50	1	609	2	3	10
anti-TNF + AZA/6-MP	0	3	12	0	185	1	0	3
anti-TNF + MTX	0	1	2	0	42	0	1	1
Vedolizumab monotherapy	0	4	12	1	246	2	0	7
Vedolizumab + AZA/6-MP	0	0	1	0	30	0	0	0
Vedolizumab + MTX	0	0	0	0	8	0	0	0
Ustekinumab	0	2	15	0	213	2	0	3
Ustekinumab + AZA/6-MP	0	1	3	0	29	0	0	2
Ustekinumab + MTX	0	0	1	0	12	0	0	0
Tofacitinib	0	1	0	0	44	0	0	1
Corticosteroid	3	7	16	1	378	2	2	7
Immunosuppressed^*	Yes	5 (62.5%)	24 (64.9%)	98 (72.65)	3 (75.0%)	1656 (75.1%)	7 (63.6%)	5 (83.3%)	29 (64.4%)	.49

Race/ethnicity

American Indian/Alaska Native

Asian

Black

Native Hawaiian/other Pacific Islander

Non-Hispanic White

Other

Unknown

All Hispanic/
Latino

P-value

135

2205

Mean age (years)

33.9 ± 15.2

41.9 ± 16.1

43.2 ± 15.3

29.5 ± 6.6

47.2 ± 17.4

42.1 ± 16.1

44.1 ± 14.9

41.4 ± 18.9

.001

Sex

Male

3 (37.5%)

19 (51.4%)

65 (48.2%)

0 (0.0%)

1024 (46.4%)

6 (54.5%)

3 (50.0%)

18 (40.0%)

.62

BMI

28.0 ± 5.7

25.3 ± 5.9

29.8 ± 8.0

25.5 ± 3.7

28.0 ± 6.5

26.3 ± 6.0

27.8 ± 5.7

25.5 ± 5.7

.001

Diagnosis

Crohn’s disease

5 (62.5%)

16 (43.2%)

98 (72.6%)

1 (25.0%)

1371 (62.2%)

5 (45.5%)

3 (50.0%)

19 (42.2%)

Ulcerative Colitis

3 (37.5%)

21 (56.8%)

37 (27.4%)

3 (75.0%)

828 (37.6%)

6 (54.5%)

3 (50.0%)

26 (57.8%)

.043

Other

0 (0.0%)

6 (0.2%)

0 (0.0%)

Mean IBD duration (years)

10.3 ± 9.8

9.4 ± 10.1

12.9 ± 9.9

9.2 ± 6.8

15.1 ± 12.6

16.2 ± 8.4

20.6 ± 16.1

12.2 ± 12.4

.016

IBD treatment

5-ASA

578

AZA or monotherapy

168

MTX monotherapy

anti-TNF monotherapy

609

anti-TNF + AZA/6-MP

185

anti-TNF + MTX

Vedolizumab monotherapy

246

Vedolizumab + AZA/6-MP

Vedolizumab + MTX

Ustekinumab

213

Ustekinumab + AZA/6-MP

Ustekinumab + MTX

Tofacitinib

Corticosteroid

378

Immunosuppressed^*

Yes

5 (62.5%)

24 (64.9%)

98 (72.65)

3 (75.0%)

1656 (75.1%)

7 (63.6%)

5 (83.3%)

29 (64.4%)

.49

Race/ethnicity
N		8	37	135	4	2205	11	6	45
Mean age (years)		33.9 ± 15.2	41.9 ± 16.1	43.2 ± 15.3	29.5 ± 6.6	47.2 ± 17.4	42.1 ± 16.1	44.1 ± 14.9	41.4 ± 18.9	.001
Sex	Male	3 (37.5%)	19 (51.4%)	65 (48.2%)	0 (0.0%)	1024 (46.4%)	6 (54.5%)	3 (50.0%)	18 (40.0%)	.62
BMI		28.0 ± 5.7	25.3 ± 5.9	29.8 ± 8.0	25.5 ± 3.7	28.0 ± 6.5	26.3 ± 6.0	27.8 ± 5.7	25.5 ± 5.7	.001
Diagnosis	Crohn’s disease	5 (62.5%)	16 (43.2%)	98 (72.6%)	1 (25.0%)	1371 (62.2%)	5 (45.5%)	3 (50.0%)	19 (42.2%)
Ulcerative Colitis	3 (37.5%)	21 (56.8%)	37 (27.4%)	3 (75.0%)	828 (37.6%)	6 (54.5%)	3 (50.0%)	26 (57.8%)	.043
Other	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mean IBD duration (years)		10.3 ± 9.8	9.4 ± 10.1	12.9 ± 9.9	9.2 ± 6.8	15.1 ± 12.6	16.2 ± 8.4	20.6 ± 16.1	12.2 ± 12.4	.016
IBD treatment	5-ASA	4	15	22	1	578	3	2	19
AZA or monotherapy	0	5	10	0	168	0	0	1
MTX monotherapy	0	0	2	0	24	0	0	0
anti-TNF monotherapy	3	7	50	1	609	2	3	10
anti-TNF + AZA/6-MP	0	3	12	0	185	1	0	3
anti-TNF + MTX	0	1	2	0	42	0	1	1
Vedolizumab monotherapy	0	4	12	1	246	2	0	7
Vedolizumab + AZA/6-MP	0	0	1	0	30	0	0	0
Vedolizumab + MTX	0	0	0	0	8	0	0	0
Ustekinumab	0	2	15	0	213	2	0	3
Ustekinumab + AZA/6-MP	0	1	3	0	29	0	0	2
Ustekinumab + MTX	0	0	1	0	12	0	0	0
Tofacitinib	0	1	0	0	44	0	0	1
Corticosteroid	3	7	16	1	378	2	2	7
Immunosuppressed^*	Yes	5 (62.5%)	24 (64.9%)	98 (72.65)	3 (75.0%)	1656 (75.1%)	7 (63.6%)	5 (83.3%)	29 (64.4%)	.49

Table 1.

Open in new tab

Demographics table for race or ethnicity.

Race/ethnicity
		American Indian/Alaska Native	Asian	Black	Native Hawaiian/other Pacific Islander	Non-Hispanic White	Other	Unknown	All Hispanic/ Latino	P-value
N		8	37	135	4	2205	11	6	45
Mean age (years)		33.9 ± 15.2	41.9 ± 16.1	43.2 ± 15.3	29.5 ± 6.6	47.2 ± 17.4	42.1 ± 16.1	44.1 ± 14.9	41.4 ± 18.9	.001
Sex	Male	3 (37.5%)	19 (51.4%)	65 (48.2%)	0 (0.0%)	1024 (46.4%)	6 (54.5%)	3 (50.0%)	18 (40.0%)	.62
BMI		28.0 ± 5.7	25.3 ± 5.9	29.8 ± 8.0	25.5 ± 3.7	28.0 ± 6.5	26.3 ± 6.0	27.8 ± 5.7	25.5 ± 5.7	.001
Diagnosis	Crohn’s disease	5 (62.5%)	16 (43.2%)	98 (72.6%)	1 (25.0%)	1371 (62.2%)	5 (45.5%)	3 (50.0%)	19 (42.2%)
	Ulcerative Colitis	3 (37.5%)	21 (56.8%)	37 (27.4%)	3 (75.0%)	828 (37.6%)	6 (54.5%)	3 (50.0%)	26 (57.8%)	.043
	Other	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mean IBD duration (years)		10.3 ± 9.8	9.4 ± 10.1	12.9 ± 9.9	9.2 ± 6.8	15.1 ± 12.6	16.2 ± 8.4	20.6 ± 16.1	12.2 ± 12.4	.016
IBD treatment	5-ASA	4	15	22	1	578	3	2	19
	AZA or monotherapy	0	5	10	0	168	0	0	1
	MTX monotherapy	0	0	2	0	24	0	0	0
	anti-TNF monotherapy	3	7	50	1	609	2	3	10
	anti-TNF + AZA/6-MP	0	3	12	0	185	1	0	3
	anti-TNF + MTX	0	1	2	0	42	0	1	1
	Vedolizumab monotherapy	0	4	12	1	246	2	0	7
	Vedolizumab + AZA/6-MP	0	0	1	0	30	0	0	0
	Vedolizumab + MTX	0	0	0	0	8	0	0	0
	Ustekinumab	0	2	15	0	213	2	0	3
	Ustekinumab + AZA/6-MP	0	1	3	0	29	0	0	2
	Ustekinumab + MTX	0	0	1	0	12	0	0	0
	Tofacitinib	0	1	0	0	44	0	0	1
	Corticosteroid	3	7	16	1	378	2	2	7
Immunosuppressed^*	Yes	5 (62.5%)	24 (64.9%)	98 (72.65)	3 (75.0%)	1656 (75.1%)	7 (63.6%)	5 (83.3%)	29 (64.4%)	.49

Race/ethnicity
		American Indian/Alaska Native	Asian	Black	Native Hawaiian/other Pacific Islander	Non-Hispanic White	Other	Unknown	All Hispanic/ Latino	P-value
N		8	37	135	4	2205	11	6	45
Mean age (years)		33.9 ± 15.2	41.9 ± 16.1	43.2 ± 15.3	29.5 ± 6.6	47.2 ± 17.4	42.1 ± 16.1	44.1 ± 14.9	41.4 ± 18.9	.001
Sex	Male	3 (37.5%)	19 (51.4%)	65 (48.2%)	0 (0.0%)	1024 (46.4%)	6 (54.5%)	3 (50.0%)	18 (40.0%)	.62
BMI		28.0 ± 5.7	25.3 ± 5.9	29.8 ± 8.0	25.5 ± 3.7	28.0 ± 6.5	26.3 ± 6.0	27.8 ± 5.7	25.5 ± 5.7	.001
Diagnosis	Crohn’s disease	5 (62.5%)	16 (43.2%)	98 (72.6%)	1 (25.0%)	1371 (62.2%)	5 (45.5%)	3 (50.0%)	19 (42.2%)
	Ulcerative Colitis	3 (37.5%)	21 (56.8%)	37 (27.4%)	3 (75.0%)	828 (37.6%)	6 (54.5%)	3 (50.0%)	26 (57.8%)	.043
	Other	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mean IBD duration (years)		10.3 ± 9.8	9.4 ± 10.1	12.9 ± 9.9	9.2 ± 6.8	15.1 ± 12.6	16.2 ± 8.4	20.6 ± 16.1	12.2 ± 12.4	.016
IBD treatment	5-ASA	4	15	22	1	578	3	2	19
	AZA or monotherapy	0	5	10	0	168	0	0	1
	MTX monotherapy	0	0	2	0	24	0	0	0
	anti-TNF monotherapy	3	7	50	1	609	2	3	10
	anti-TNF + AZA/6-MP	0	3	12	0	185	1	0	3
	anti-TNF + MTX	0	1	2	0	42	0	1	1
	Vedolizumab monotherapy	0	4	12	1	246	2	0	7
	Vedolizumab + AZA/6-MP	0	0	1	0	30	0	0	0
	Vedolizumab + MTX	0	0	0	0	8	0	0	0
	Ustekinumab	0	2	15	0	213	2	0	3
	Ustekinumab + AZA/6-MP	0	1	3	0	29	0	0	2
	Ustekinumab + MTX	0	0	1	0	12	0	0	0
	Tofacitinib	0	1	0	0	44	0	0	1
	Corticosteroid	3	7	16	1	378	2	2	7
Immunosuppressed^*	Yes	5 (62.5%)	24 (64.9%)	98 (72.65)	3 (75.0%)	1656 (75.1%)	7 (63.6%)	5 (83.3%)	29 (64.4%)	.49

Abbreviations: 5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; AZA: azathioprine; anti-TNF: anti-tumor necrosis factor; MTX: methotrexate.

^*Immunosuppressed includes those on azathioprine, methotrexate, anti-TNF, ustekinumab, tofacitinib, and/or corticosteroid.

This Feature Is Available To Subscribers Only